The calcium channel blocker controversy in perspective

Cardiology

Volumn 88, Issue SUPPL. 1, 1997, Pages 66-72

  Zanchetti, Alberto ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b Ctr Fisiol Clin/Ipertensione   (Italy)

Author keywords

Antihypertensive treatment; Calcium channel blockers; Coronary heart disease

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RESERPINE;

ANTIHYPERTENSIVE THERAPY; BREAST CARCINOMA; CONFERENCE PAPER; HEART INFARCTION; HYPERTENSION; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0031021305     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000177470     Document Type: Conference Paper

References (28)

1. Frohlich ED, Zanchetti A: Antihypertensive therapy: Safety and efficacy of drugs and publications. J Hypertens 1996;14:273-275.
2. Jick H, Slone D, Shapiro S, Heinonen OP, Hartz SC, Miettinen OS, Vessey MP, Lawson DH, Miller RR: Boston Collaborative Drug Surveillance Program. Reserpine and breast cancer. Lancet 1974;ii:669-671.
3. Armstrong B, Stevens N. Doll R: Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet 1974;ii:672-675.
4. Heinonen OP, Shapiro S, Tuominen L, Turenen MI: Reserpine use in relation to breast cancer. Lancet 1974;ii:675-677.
5. Laska EM, Siegel C, Meisner M, Fischer S, Wanderung J: Matched-pairs of reserpine use and breast cancer. Lancet 1975;ii:296-300.
6. O'Fallon WM, Labarthe DR, Kurland LT: Rauwolfia derivatives and breast cancer. Lancet 1975;ii:292-296.
7. Mack TM, Henderson BE, Gerkins VR, Arthur M, Baptista J, Pike MC: Reserpine and breast cancer in a retirement community. N Engl J Med 1975;292:1366-1371.
8. Lilienfeld AM, Chang L, Thomas DB, Levin ML: Rauwolfia derivatives and breast cancer. Johns Hopkins Med J 1975;139:41-50.
9. Aromaa A, Hakama M, Hakulinen T, Saxen E, Teppo L, Idanpaan-Heikkila J: Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: A nation-wide case-control study in Finland. Int J Cancer 1976;18:727-738.
10. Armstrong B, Skegg D. White G, Doll R: Rauwolfia derivatives and breast cancer in hypertensive women. Lancet 1976;ii:8-12.
11. Kewitz H, Jesdinsky HJ. Schroter PM, Lindtner E: Reserpine and breast cancer in women in Germany. Eur J Gin Pharmacol 1977;11:79-83.
12. Christopher LJ, Crooks J. Davidson JF, Erskine ZG, Gallon SC, Moir DC, Weir RD: A multicentre study of rauwolfia derivatives and breast cancer. Eur J Clin Pharmacol 1977;11:409-417.
13. Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trials: Risk factor changes and mortality results. JAMA 1982;248:1465-1477.
14. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease, 2, Short-term reductions in blood pressure: Overview of randomized trials in their epidemiological context. Lancet 1990;335:827-838.
15. Grobbee DE, Hoes AW: Non-potassium-sparing diuretics and risk of sudden cardiac death. J Hypertensl995;13:1539-1545.
16. Hoes AW, Grobbee DE, Lubsen J, Man in't Veld AJ, van der Does E, Hofman A: Diuretics, β-blockers and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995;123:481-487.
17. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X. Cobb L, Rantahazju PM, Copass MK, Wagner EH: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852-1857.
18. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DF, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
19. Pahor M, Guralnik JM, Foley DJ, Carbonin P: Long-term survival and uses of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191-1197.
20. Aursnes I, Litleskare I, Froyland H, Abdelnoor M: Association between various drugs used for hypertension and risk of myocardial infarction. Blood Press 1995;4:157-163.
21. Furberg CD, Psaty BM, Meyer JN: Nifedipine. Dose-related increase in mortality in patients with coronary heart disease, Circulation 1995;92:1326-1331.
22. Opie LH, Messerli FM: Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068-1073.
23. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD: Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995;91:2274-2282.
24. Mayes LC, Horwitz RI, Feinstein AR: A collection of 56 topics with contradictory results in case-control research. Int J Epidemiol 1988;17:680-685.
25. Mancia G, van Zwieten PA: How safe are calcium antagonists in hypertension and coronary heart disease? J Hypertens 1996;14:13-17.
26. Zanchetti A: Current position of calcium antagonists in hypertension. J Hypertens 1996;14(suppl 3), in press.
27. The Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure: The Fifth Report of the Joint National Committee on Detection. Evaluation, and Treatment of High Blood Pressure (JNC-V) 1992. Ann Intern Med 1993;153:154-183.
28. Guidelines Sub-Committee: 1993 Guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993;11:905-918.